Search Results - maria+parkhurst

2 Results Sort By:
HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K
Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target PIK3CA mutations to treat patients with tumors expressing these mutations in the context of HLA-DPA1*01:03:01, HLA-DPB1*04:01:01 or HLA-DRB1*04:01. Description of Technology: Phosphatidylinositol-4,5-biphosphate...
Published: 12/20/2024   |   Inventor(s): Steven Rosenberg, NIkolaos Zacharakis, S M Rafiqul Islam, Samantha Seitter, Maria Parkhurst, Frank Lowery
Keywords(s):  
Category(s): TherapeuticArea, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing
T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy
Abstract: The tumor protein p53 is a cell cycle regulator. It responds to DNA damage by triggering the DNA repair pathway and allowing cell division to occur or inducing cell growth arrest, cellular senescence, and/or apoptosis. p53 therefore acts as a tumor suppressor by preventing uncontrolled cell division. However, mutations in p53 that impair...
Published: 4/8/2024   |   Inventor(s): Drew Deniger, Parisa Malekzadeh, Winifred Lo, Rami Yoseph, Paul Robbins, Maria Parkhurst, Anna Pasetto, Yong-Chen Lu, Steven Rosenberg
Keywords(s): Immunotherapy, p53, Rosenberg, T Cell Receptor, TCR, Tumor Protein P53
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology